News

The study suggests memantine could be considered a first-line treatment equal to behavioral therapy in the treatment process.

Study investigators evaluated the blood-brain barrier penetrance and lipophilicity of the narrow-spectrum, third-generation tetracycline-class oral antibiotic used for acne treatment.

In part 1 of this Frontline Forum series, Joshua Zeichner, MD, FAAD; Hilary Baldwin, MD; Zoe Diana Draelos, MD; Aaron S. Farberg, MD, FAAD; and Leon H. Kircik, MD, discuss the main pillars of acne and topical treatments available for patients with acne.

In this episode, Mona Shahriari, MD, discusses what dermatologists and patients with atopic dermatitis can expect as we transition from winter to spring, as well as new and emerging treatments and technologies for managing atopic dermatitis that she’s looking ahead to as the year progresses.

The AbbVie company announced their partnership with the grant program to encourage women to own their own businesses.

Researchers say disease severity, site, and comorbidities may lower a patient’s quality of life as they navigate hidradenitis suppurativa.

The alert advises attendees that are not fully vaccinated to quarantine and monitor symptoms for 21 days.

In this week’s Pointers with Dr Portela, the 208SkinDoc reviews the best skin care brands for sensitive skin in 2023.

The treatment for adults and adolescents with the type 2 inflammatory skin condition has been accepted for FDA review.

A prototype for a coral-reef-friendly sunscreen is more effective at preventing sunburn in mice than existing sunscreens.

Novan’s expected PDUFA date is January 5, 2024.

Researchers conducted a pooled data analysis using previous study data to determine the cream’s efficacy in patients ages 12 and up.

JNJ-2113 met primary endpoints in the FRONTIER 1 clinical trial.

Following a systematic review and observational study meta-analysis, researchers have uncovered an association between hidradenitis suppurativa and several atopic diseases.

The commander-in-chief’s cancerous tissue was successfully removed last month.

ICYMI, this week we had stories about accepted NDAs and sBLAs for VP-102 and nivolumab, overviews of rare dermatologic diseases for National Rare Disease Day, antioxidants for vitiligo and mental health, and more.

Transplant patients are at a higher risk of nonmelanoma carcinomas due to immunosuppressive therapies.

Following 2 phase 3 trials, the European Medicines Agency Committee for Medicinal Products for Human Use gives positive opinion on the use of ruxolitinib cream as a treatment for facial-involved non-segmental vitiligo.

Convatec’s InnovaBurn device manages surgical wounds and burns, including second-degree burns.

Innovative devices are always coming to the forefront of dermatology and contribute to patient satisfaction.

Research has begun to explore natural compounds that address the oxidative stress, autoimmunity, and altered melanogenesis that drive vitiligo pathogenesis.

Following a 72-week safety and efficacy trial, researchers have determined that 1% glycopyrronium bromide cream can reduce symptoms of hyperhidrosis.

Latin America presents a patchwork of challenges and opportunities in vitiligo management according to a review published in the Journal of Dermatological Treatment.

In this week’s Pointers with Dr Portela, the 208SkinDoc discusses basal cell carcinoma and Mohs surgery related to Jill Biden's most recent skin cancer diagnosis.

Each month, Dermatology Times® features a roundup of products trending in skin care. Find out what products are popular for the month of February.

Today is Rare Disease Day. The Food and Drug Administration (FDA) defined a rare disease as a condition affecting less than 200,000 people in the United States.

Learn more about what in-depth topics were covered in the February 2023 issue of Dermatology Times®.

The autoinflammatory condition is associated with mutations in the NOD2 gene and usually affects children younger than 4 years.

VP-102 could be the first FDA-approved treatment for molluscum contagiosum.

Nivolumab for completely resected stage IIB or IIC melanoma is also validated by the European Medicines Agency.